# Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients

> **NCT06556004** · PHASE1 · UNKNOWN · sponsor: **University of Chile** · enrollment: 20 (actual)

## Conditions studied

- Melanoma Stage IIIc
- Melanoma Stage IV

## Interventions

- **BIOLOGICAL:** TRIMELVAX

## Key facts

- **NCT ID:** NCT06556004
- **Lead sponsor:** University of Chile
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-02
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556004, "Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06556004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*